Klaria Pharma
Klaria Year-End Report 2023
Fourth quarter of 2023
Remaining business operations
- Net sales 0.0 MSEK (2.2 MSEK)
- Other income 0.2 MSEK (0.2 MSEK)
- R&D costs for the quarter amounted to 1.5 MSEK (8.6 MSEK)
- Profit after tax amounted to -7.9 MSEK (-12.9 MSEK)
- Earnings per share for the quarter amounted to -0.07 SEK (-0.22 SEK)
- Cash flow from operating activities amounted to -13.3 MSEK (-10.7 MSEK)
Business operations for sale
- Profit after tax amounted to -1.6 MSEK
The period January–December 2023
Remaining business operations
- Net sales 0.0 MSEK (5.9 MSEK)
- Other income 0.2 MSEK (0.7 MSEK)
- R&D costs for the period amounted to 4.5 MSEK (51.4 MSEK)
- Profit after tax amounted to -18.4 MSEK (-63.8 MSEK)
- Earnings per share for the period amounted to -0.18 SEK (-1.10 SEK)
- Cash flow from operating activities amounted to -15.4 MSEK (-49.8 MSEK)
Business operations for sale
- Profit after tax amounted to -17.4 MSEK
- Earnings per share for the quarter amounted to -0.17 SEK
| Datum | 2024-02-29, kl 16:30 |
| Källa | Cision |
100% cashback på aktiecourtage! Handla aktier på eToro och få tillbaka 100% av ditt courtage i 3 månader. Hur? Registrera dig här nu direkt för att ta del av erbjudandet.